CStone Pharmaceuticals Streamlines Company Secretary and Authorized Representative Roles

CStone Pharmaceuticals ( (HK:2616) ) has issued an announcement.

CStone Pharmaceuticals has announced changes to its corporate governance structure, with the Hong Kong Stock Exchange confirming that current joint company secretary Ms. Weicong Ni will be fully qualified to serve as company secretary when an existing waiver expires on January 17, 2026. As a result, joint company secretary and authorized representative Ms. Mei Yee Yung will step down from both roles effective February 6, 2026, leaving Ms. Ni as the sole company secretary and an authorized representative alongside executive director Dr. Jianxin Yang, while Ms. Yung will remain the company’s Hong Kong process agent, ensuring continuity in regulatory and legal liaison functions. These changes streamline CStone’s secretarial and representation arrangements and signal a maturing compliance framework as the company aligns more tightly with Hong Kong listing requirements, with no disagreements reported between the departing officer and the board.

The most recent analyst rating on (HK:2616) stock is a Sell with a HK$5.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.

More about CStone Pharmaceuticals

CStone Pharmaceuticals, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative oncology therapies for the China and global markets.

Average Trading Volume: 9,019,621

Technical Sentiment Signal: Hold

Current Market Cap: HK$7.73B

See more insights into 2616 stock on TipRanks’ Stock Analysis page.